| DC70931 |
ZED3197
|
ZED3197 (ZED-3197) is a novel peptidomimetic direct-acting, potent and selective inhibitor of human FXIIIa, inhibits human plasma derived FXIII‐A2B2 and the recombinant cellular form (FXIII‐A2) with IC50 of 10 and 14 nM, respectively.ZED3197 strongly blocks FXIII‐A2 from mouse, rat, rabbit, dog, and cynomolgus monkey (IC50 8-30 nM), is a significantly weaker inhibitor of FXIII‐A2 from pig (IC50=220 nM).ZED3197 displays 20‐fold to 3000‐fold selectivity against human transglutaminases TG1, TG2, TG3, and TG7.ZED3197 prolonged clot formation, reduced clot firmness, and facilitated clot lysis in whole human blood without affecting the clotting time, indicating minimal impact on hemostasis.ZED3197 effectively decreased the weight of clots and facilitated flow restoration without prolongation of the bleeding time in vivo. |
| DC46132 |
Milvexian
|
Milvexian (BMS-986177), an effective antithrombotic agent, is an orally-bioavailable, reversible and direct inhibitor of human and rabbit factor XIa (FXIa) with Ki of 0.11, and 0.38 nM, respectively. |
| DC79846 |
Bz-Pro-Phe-Arg-pNA hydrochloride
|
Bz-Pro-Phe-Arg-pNA (Bz-PFR-pNA) hydrochloride is a chromogenic peptide substrate for plasma and glandular Kallikrein, cysteine proteinase (Cruzipain) and Trypsin. Bz-Pro-Phe-Arg-pNA hydrochloride can be used in Factor XII assay. |
| DC79222 |
BMS-344577
|
BMS-344577 (Compound 22) is a potent and orally active factor Xa inhibitor (IC50 = 4 nM, EC2xPT = 7 μM). BMS-344577 shows potent CYP3A4 inhibition activity (IC50 = 0.3 μM). BMS-344577 can be used for the research of cardiovascular disease. |
| DC79218 |
RPR 130737
|
RPR 130737 is a selective, potent and competitive inhibitor for factor Xa with a Ki of 2.4 nM. RPR 130737 shows selectivity of more than 1000-fold over thrombin, activated protein C, plasmin, tissue-plasminogen activator and trypsin. RPR 130737 can prolong plasma activated partial thromboplastin time and prothrombin time. RPR 130737 shows no effect on platelet aggregation. RPR 130737 can be used for the research of cardiovascular disease, such as thrombosis. |
| DC79054 |
DPC423 free base
|
DPC423 free base is a selective and orally active factor Xa inhibitor with a Kis of 0.15 (human) and 0.3 (rabbit) nM. DPC423 free base exhibits Kis of 60, 61 and 6000 nM against human trypsin, plasma kallikrein and thrombin. DPC423 free base blocks the formation of prothrombinase complex, reduces thrombin production, inhibits fibrin formation and platelet activation. DPC423 free base has demonstrated antithrombotic effects in animal models, and when used in combination with Aspirin, it shows a strong synergistic effect. DPC423 free base can be used for the study of anticoagulation of arterial thrombosis. |
| DC79030 |
ZK-813039
|
ZK-813039 is a potent and orally active factor Xa inhibitor. ZK-813039 can prolong prothrombin time. ZK-813039 can be used for the research of cardiovascular disease. |
| DC78739 |
DX-9065a free base
|
DX-9065a (free base) is a selective, nonpeptidic, and orally active factor Xa (FXa) inhibitor with a Ki of 41 nM for human FXa. DX-9065a (free base) has low activity against other serine proteases. DX-9065a (free base) has strong anticoagulant actions. |
| DC78234 |
BMS-269223
|
BMS-269223 is a potent, selective and orally active factor Xa inhibitor (Ki = 6.5 nM, EC2xPT = 32 μM). BMS-269223 can prolong prothrombin time and inhibit thrombosis formation. BMS-269223 can be used for the research of cardiovascular disease. |
| DC71808 |
Edoxaban hydrochloride
|
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research. |
To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
